IPF PPF SSc-ILD Mechanism of Action Prescribing information Advancing PF Care Previous Next FACE IPF HEAD ON and modify disease progression by slowing lung function decline Safety Profile of OFEV 07/06/2024 | Author: Boehringer Ingelheim Document ID: PC-SA-102973 | Expiry Date: 06/07/2028 Ofev PPF Identify Patients With RA-ILD Who Can Benefit From OFEV How to understand and manage limited cutaneous SSc-ILD Safety Profile of OFEV Treatment of patients with PPF and CTD-ILD Related content Read more 3:43 Treatment of patients with PPF and CTD-ILD PC-SA-102964 (May 2028 ) Watch now Opens in new tab Read more PDF How to understand and manage limited cutaneous SSc-ILD PC-SA-102972 (June 2028 ) Download Opens in new tab Read more PDF Identify Patients With RA-ILD Who Can Benefit From OFEV PC-SA-101935 (August 2026 ) Download Opens in new tab Home Respiratory | Therapeutic Area Ofev Disease State Safety Profile of OFEV
Read more 3:43 Treatment of patients with PPF and CTD-ILD PC-SA-102964 (May 2028 ) Watch now Opens in new tab
Read more PDF How to understand and manage limited cutaneous SSc-ILD PC-SA-102972 (June 2028 ) Download Opens in new tab
Read more PDF Identify Patients With RA-ILD Who Can Benefit From OFEV PC-SA-101935 (August 2026 ) Download Opens in new tab
